Cargando...
Era of direct acting antivirals in chronic hepatitis C: Who will benefit?
In the era of highly effective direct acting antiviral (DAA) drugs for the treatment of chronic hepatitis C (CHC) infection, where eradication is almost ensured with minimal side effects, all hepatitis C carriers should benefit theoretically. In the real world setting however, only a small proportio...
Gardado en:
| Publicado en: | World J Hepatol |
|---|---|
| Autor Principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Baishideng Publishing Group Inc
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4621468/ https://ncbi.nlm.nih.gov/pubmed/26523206 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4254/wjh.v7.i24.2543 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|